

Holme, I. M. K., Kjeldsen, S. E. (2015). Long-term survival in the randomized trial of drug treatment in mild to moderate to moderate hypertension of the Oslo study 1972–3. *European journal of internal medicine*, 26, 123-126.

Dette er siste tekst-versjon av artikkelen, og den kan inneholde små forskjeller fra forlagets pdf-versjon. Forlagets pdf-versjon finner du på www.elsevier.com: <http://dx.doi.org/10.1016/j.ejim.2015.01.013>

This is the final text version of the article, and it may contain minor differences from the journal's pdf version. The original publication is available at www.elsevier.com: <http://dx.doi.org/10.1016/j.ejim.2015.01.013>

Long-term survival in the randomized trial of drug treatment in mild to moderate hypertension of the Oslo Study 1972-3

Ingar Holme^a, PhD, Sverre Kjeldsen^b, MD, PhD

^a Oslo Center of biostatistics and epidemiology , Research Support Services, Oslo University hospital, Oslo, Norway and Norwegian School of Sports Sciences, Department of Sports medicine, Oslo, Norway.

^b Department of Cardiology, Oslo University Hospital, Oslo, Norway

Contact information:

Ingar Holme, PhD, P.O.Box 4950 Nydalen, N-0424 Oslo, Norway.

Phone: +4722117927/Mob:+4791325542

e-mail: ingar.holme@ous-hf.no

Abstract

BACKGROUND: In the Oslo cardiovascular study of 1972-3 a 5-year randomized trial in mild to moderate hypertension was performed. Several changes in treatment practices have been recommended since that time. We followed the mortality patterns up to 40 years.

METHODS: Invited to the Oslo study screening were 25915 middle-aged men and 16203 (63 %) participated. Reexaminations were done to select suitable participants into the trial. Men had blood pressure 150-179/95-109 mmHg and the active group (n=406) was treated with thiazides, alpha-methyldopa and propranolol versus untreated controls (n=379). Cox regression analysis was used for statistical analyses.

RESULTS There was no trend towards reduction in total mortality by treatment. A nominally significant increase in risk of death at first myocardial infarction was observed in the trial treatment group across the follow-up period, HR=1.51 (1.01-2.25); P=0.042). The excess risk developed rapidly during the first 15 years, but the gap between the groups diminished to a large extent during the next 15 years, but the curves stayed at a certain distance for the last 10 years. Cerebrovascular death tended to be non-significantly reduced, HR=0.85 (0.52-1.41).

CONCLUSIONS: Drug treatment of mild hypertensive men initiated in the 1970s did not reduce mortality at first MI or total mortality. However, during the period (late 1980s and whole 1990s), when large changes in hypertension treatment practices occurred into regimes with more use of combination therapies including metabolically neutral drugs at lower doses, beneficial effects on MI mortality could be observed.

KEYWORDS: mild hypertension, long-term mortality, randomized drug trial, antihypertensive treatment

Word count: 242

The Oslo study of cardiovascular disease (CVD) in 1972-3 was the first in a series of similar studies performed by the National Health Service in different counties of Norway.¹ In several counties

screenings were repeated after some years and the data collected have provided much of the basic knowledge about cardiovascular disease (CVD) epidemiology in Norway.²⁻⁹

One major purpose of the screening in Oslo was to recruit participants to two randomized controlled trials among supposedly healthy men with a high risk of developing CVD. The background was that myocardial infarction (MI) incidence and mortality had increased at all years from World War II and had reached epidemic proportions. Prevention and treatment of the major risk factors were regarded as cornerstones to stop the epidemic. One of the trials was a treatment trial of 785 mild to moderate hypertensive men who were randomized to drug treatment or no treatment. Drug treatment consisted mainly of hydrochlorothiazide 50 mg daily and in addition if necessary methyldopa twice daily was added. If side effects occurred propranolol up to 160 mg twice daily was given. The other was a combined diet and antismoking trial in men with high total serum cholesterol levels and 80 % smokers. Both trials stopped at the end of the 1970s and detailed results have been reported.¹⁰⁻¹¹ In light of the drastic changes since the 1970s in dietary and smoking habits, the large exchange to modern and metabolically neutral antihypertensive drugs and the massive use of statins in secondary coronary prevention and other high-risk populations with a reduction of coronary mortality in middle aged men to less than a fourth, the long term mortality outcomes of the trials would be difficult to predict. We know of no randomized hypertension drug trial that has been followed with respect to cardiovascular and total mortality for up to 35 years after its close.

Thus, the purpose of this study was to report up to 40 years survival results with respect to death at first MI, cerebrovascular and all-cause mortality in the mild to moderate hypertension trial.

MATERIAL AND METHODS

All men in Oslo born 1923-1932 were in 1972/73 invited to a screening examination for CVD. Of the 25915 eligible 16203 (63 %) participated. They were asked to fill in a questionnaire about prevalent CVD and diabetes. Those without such diseases were called healthy men and in them two

examinations followed to select suitable participants to two planned randomized trials³. In the mild to moderate hypertension trial men with blood pressure 150-179/95-109 mmHg were included.

Men with a higher blood pressure than those included in the trial were referred to the general practice system. The trial has previously been followed up with respect to coronary morbidity and mortality up to 10 years¹². The survivors (n=12764) in the screened population were invited to a second screening examination in year 2000. However, only 6014 men (45 %) of the invited participated and among the trial groups only 144 (35.2 %) and 134 (35.9 %) attended in the active and control group respectively. The present study is extended as a survey only to December 31st 2011 with respect to mortality at first MI, cerebrovascular and total mortality. Thus, no morbidity data other than prevalence of some diseases at the year 2000 screening were available through the whole follow up period. Statistics Norway added mortality data to the Oslo study data file according to permissions given by the Data Inspectorate and tax authorities, Department of health and the project was approved by the regional ethics committee for medical research.

STATISTICAL ANALYSIS

Rates per 1000 observation years and differences between rates with 95 % confidence limits were calculated. Cox proportional hazards regression models were used and time to death, time to death at first MI or time to cerebrovascular death were dependent variables. Group codes were exposure factors. Hazard ratios were calculated with 95 % confidence limits. The log rank test was used to test for differences between treatment groups with respect to survival. Kaplan-Meier curves were made by the STATA 13 software.

RESULTS

Table 1 shows some risk factors at screening in year 1972-73 by treatment group. They were fairly balanced as could be expected by design and demonstrate a population with normal bodyweight and mild to moderate blood pressure levels. The daily smoking proportion was

just above the average as compared to the whole screened population (data not given). When these men were invited to a new screening in year 2000 many had died and many declined to participate once more, but **Table 2** gives an indication that groups were still fairly balanced on major coronary risk factors. In this selected group the level of systolic blood pressure was still high, but also glucose stayed somewhat elevated. **Table 3** demonstrates small differences between proportions of men with experienced diabetes, MI or stroke by treatment group and so do use of antihypertensive or cholesterol lowering drugs.

The hypertension trial treatment group had a nominally significant increased risk of death at first MI as compared to controls (HR=1.51; 95 % CI: 1.01-2.25; P=0.042), **Figure 1**. The risk difference developed proportionally the first 15 years. In the next 15 years from late 1980s to beginning of year 2000s the gap narrowed. During the last 10 years curves went more parallel. Cerebrovascular death was non-significantly reduced, HR=0.87 (0.52-1.43), but number of such deaths was only 61. Total mortality was similar between the two treatment groups throughout the follow-up period, **Figure 2**.

DISCUSSION

This study showed an excess MI mortality risk, a slight and non-significant decrease in cerebrovascular death and equal total mortality by active treatment as compared to control. Unfortunately, the negative development of death at first MI continued in the hypertension trial participants up to 40 years of follow-up. The trend at close out of the trial was also confirmed at 10 years follow-up¹². However, after about 15 years of follow up, the gap between the curves seemed to shrink for the next 15 years, but continued later on without fully catching up the lower risk in the control group. The interpretation of this finding is difficult since no regular clinical follow up was made on these men. Our data only stems from a mortality survey follow up at end of 2011. In year 2000 the re-screened population among the survivors had a low (45 %) participation frequency and this was even lower in the trial participants due to their higher mortality. Among these the prevalence

of drug treatment was 80.9 % in the active and 82.4 % in the control group men. Also other conventional risk factors were fairly equal in this selected subgroup at that time. This gives an indication that both groups were equally treated at that time and is thus consistent with the parallel MI survival curves observed during the last 10 years of follow-up. It is unknown to what degree old treatment modalities used in the hypertension trial have been exchanged with effective and more metabolically neutral antihypertensive drugs, since no such effort was made systematically. In Norway there was generally a great exchange of new drugs such as ACE inhibitors, angiotensin II blockers or calcium antagonists with more combination therapy each prescribed at lower doses during late 1980s and through the 1990s due to anticipated favorable results in large clinical trials. This is documented by prescription statistics during these years.¹³ There was a high use of thiazides into the beginning of the 1980s, but then more calcium channel blockers were prescribed together with less use of thiazides that was almost not used in the period 1990 to about 2005, when new statements about use of thiazides as basic choice of drug were issued from the Government Health department but again abandoned in 2010. From about 1995 use of ACE and AII inhibitors increased rapidly and at the end of the follow up period defined daily dose per 100000 inhabitants per day of all hypertensive use (covering somewhat more diagnoses than pure hypertension) more than doubled in the population as compared to that in 1985 and more than 6-doubled from 1995¹³. These massive changes in treatment modalities may have contributed but cannot be proved to the narrowing gap in heart disease mortality. However, not until 2002 came the first outcome trial showing newer treatment being favorable to older treatment¹⁴ and this was substantiated in 2005¹⁵.

A possible reason for the meager effect of treatment on cerebrovascular mortality could be a dilution effect by initiating antihypertensive treatment in those control group men who developed a non-fatal cerebrovascular insult during the trial period. There it was documented that the incidence of stroke was significantly higher in the control as compared to the treatment group¹¹. Also, different antihypertensive drugs have different effects on cardiovascular endpoints even if blood pressure is reduced to the same level¹⁴⁻¹⁷. In addition, as mentioned above, antihypertensive treatment may have developed at a similar frequency the last years of follow up.

It came as no surprise that total mortality came out neutral between the two groups, since effects on cerebrovascular and MI mortality almost cancelled each other out.

Meta analyses including both mild to moderate or only mild hypertension participants have so far not demonstrated significant benefits on coronary heart disease events but rather limited to cerebrovascular events¹⁸⁻¹⁹. In the meta analysis including mild hypertension trials only and where the Oslo trial was not included cerebrovascular events was not significantly reduced and the effect on coronary heart disease events was in the adverse direction (Relative risk 1.12, 95 % CI 0.80-1.57)¹⁹. Thus, our trial may have overestimated the negative effects of antihypertensive treatment on MI mortality as well as underestimated the effect on cerebrovascular events, but the crude estimates for coronary disease still lie within the confidence limits from the meta-analysis but outside of it for cerebrovascular events. Again, comparisons are hard to interpret since different treatment regimens, duration of follow up and endpoints were used. We know of no other long-term follow up of randomized drug trials in mild to moderate hypertension after their close, but from our data it does not seem to be indifferent in the long term how blood pressure is reduced with regard to CHD prevention although this interpretation must be cautious.

There is a need to get more data on the effect of antihypertensive treatment to reduce MI risk. . So far such treatment is largely shown to be beneficial to cerebrovascular disease and some combined endpoints of cardiovascular disease in mild to moderate hypertension.

STUDY STRENGTHS AND LIMITATIONS

Mortality follow-up in Norway is complete through its individual 11-digit person number and emigrants are censored at time of emigration. Efficacy on blood pressure reduction was high as documented in the first publication¹¹. There are several limitations to the study: lack of regular clinical follow up of these men makes it unknown how hypertension and other occurring diseases

have been treated in this period; cardiovascular morbidity data have not been available; information from the rescreening of the surviving men in year 2000 only included 35 % of the original cohort due to higher than average mortality and selective attendance; the study was originally underpowered with no placebo control and was confined to men only.

CONCLUSIONS

In the mild to moderate hypertension trial the drug treated group had an excess MI risk during follow up. A high degree of knowledge among medical practitioners regarding effective antihypertensive drug treatment in Norway has probably had an effect on the closing gap in MI mortality in the middle of the period. We learned that the correct mode of such treatment is of great importance. No differences between treatment groups were found with regard to total mortality.

References

1 Leren P, Askevold EM, Foss OP, et al. The Oslo Study. Cardiovascular disease in middle-aged and young Oslo men. *Acta Medica Scandinavica*.1975 (Suppl 588):1-38.

2 Bjartveit K, Foss OP, Gjervig T, Lund-Larsen PG. The cardiovascular disease study in Norwegian counties. Background and organization. *Acta Medica Scandinavica* 1979;(Suppl 634):1-70.

3 Lund-Larsen PG. ECG in Health and Disease. ECG findings in relation to CHD risk factors, constitutional variables and 16-year mortality in 2990 asymptomatic Oslo men aged 40-49 years in 1972. The Oslo Study. *ISM monograph series no 30*. University of Tromsø. 1994.

4 Tverdal A. A mortality follow-up of persons invited to a cardiovascular disease study in 5 areas in Norway (monograph). *National Health Screening Service, Oslo*. 1989.

5 Thürmer H. Risk factors for, and 13-year mortality from cardiovascular disease by socioeconomic status: A study of 44690 men and 17540 women, ages 40-49. *ISM Monograph series no 26*. University of Tromsø, Norway. 1993.

6 Holme I, Lund Håheim L, Hjermmann I. Prediksjons funksjoner for 21 års utvikling av hjerteinfarkt fra Oslo undersøkelsen 1972/73. *Tidsskr Nor Lægeforen* 2003; 123:1050-1054.

7 Holme I, Tonstad S. Risikofaktorer og dødelighets oppfølging av Oslo undersøkelsen 1972-73. *Tidsskr Nor Lægeforen* 2011;131:456-460.

8 Thelle DS, Førde OH. The Tromsø Heart Study. Methods and main results of the cross sectional study. *Acta Med Scand* 1976; 200:107-118.

9 Førde OH, Thelle DS. The Tromsø Heart Study: risk factors for coronary heart disease related to the occurrence of myocardial infarction in first degree relatives. *Am J Epidemiol* 1977; 105:192-199.

10 Hjermmann I, Byre KV, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. *Lancet* 1981:1303-1310.

11 Helgeland A. The Oslo Study. Treatment of mild hypertension: A 5-year controlled drug trial. *Am J Med* 1980; 69:725-732.

12 Leren P, Helgeland A. Coronary heart disease and treatment of hypertension. *Am J Med* 1986; 80 (suppl 2A):3-6.

13 Blix HS, Landmark K, Selmer R, Reikvam A. Forskrivning av antihypertensive legemidler 1975-2010. *Tidsskr Nor Lægeforen* 2012; 122:1224-1228.

14 Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; 359:995-1003.

15 Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Östergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet* 2005; 366: 895-906.

16 Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodopine: the VALUE randomized trial. *Lancet* 2004;363:2022-2031.

17 Jamersen K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med* 2008;359:2417-2428.

18 Gueyffier F1, Froment A, Gouton M. New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. *J Hum Hypertens*. 1996 Jan;10(1):1-8.

19 Diao D, Wright JM, Cundiff DK, Geuyffier F. Pharmacotherapy for mild hypertension. [Cochrane Database Syst Rev](#). 2012 Aug 15;8:CD006742. doi: 10.1002/14651858.CD006742.pub2

Funding: This study had no extra funding.

Conflict of interest: IH has no disclosure to announce. SEK announces moderate honorarias for consulting (Bayer, Medtronic, Serodus, Takeda) and lectures (AZ, Bayer, Medtronic, MSD, Novartis, Takeda) and unrestricted grant support from AZ and Pronova, all directed to research accounts.

Authorship: Both authors had access to the data and played a role in writing the manuscript.

Table 1 Mean (SD) of some risk factors at screening in 1972-73 and in year 2000 by treatment group.*

Screening 1972-73	Treatment group (n=406)	Control group (n=379)
Systolic blood pressure (mmHg)	163.8 (11.6)	162.9 (10.4)
Diastolic blood pressure (mmHg)	100.3 (10.1)	101.2 (9.1)
Bodyweight (kg)	81.7 (11.5)	82.1 (11.2)
Daily smoking (N, % Yes)	200 (52.8)	197 (48.5)
Screening year 2000		
Attendants (N, %)	144 (35.4)	134 (34.5)
Systolic blood pressure (mmHg)	157.6 (20.2)	158.4 (19.7)
Diastolic blood pressure (mmHg)	86.5 (11.2)	84.6 (10.0)
Bodyweight (kg)	82.4 (12.3)	82.7 (13.0)
Total serum cholesterol (mmol/L)	5.72 (1.11)	5.74 (1.16)
Triglycerides (mmol/L)	1.87 (0.84)	1.79 (0.96)
High density cholesterol (mmol/L)	1.41 (0.40) 6.08 (1.64)	1.42 (0.42) 2.70 (6.56)
Serum glucose (mmol/L)		
Daily smoking (n, %)	21 (15.3)	16 (11.1)
Previous smoking (n, %)	70 (51.1)	91 (63.2)
Never smoking (n, %)	46 (33.6)	37 (25.7)

* Number of valid measurements may vary due to some incompleteness in some variables.


Table 2 Disease prevalence and drug use at year 2000 by attending men per treatment group.

Diseases and drug use	Treatment group (n=144)	Control group (n=134)
Diabetes	22 (15.3)	14 (10.4)
Myocardial infarction	24 (16.9)	27 (20.1)
Cerebral stroke	12 (8.5)	15 (11.3)
Use of antihypertensive drugs	115 (80.4)	112 (82.4)
Use of cholesterol lowering drugs	45 (33.3)	39 (30.5)

Table 3 First myocardial infarction and total death risk through 40 years in the mild hypertension trial in Oslo

Group	MI deaths	Rate per 1000 obs years	Number of deaths	Death rate per 1000 obs years
Treatment (n=406)	63	5.3	296	25.1
Control (n=379)	39	3.5	272	24.7
Difference (95 % CI)		-1.8 (-3.5-(-0.7))		-0.4 (-44.6-37.2)
Hazard ratio		1.51 (1.01-2.26)		1.02 (0.87-1.21)

MI= myocardial infarction; CI= confidence interval.



Figur 2 Kaplan-Meier survival estimates of no MI in the mild hypertension trial by treatment group.




Figure 3 Kaplan-Meier survival estimates by treatment group in the mild hypertension trial.